How to Pay for Memory Care: Navigating Costs, Safety, and Medicaid Spend-Down

Your Medicare Plan’s Star Rating May Be a Mirage This Year — 3 Things to Check Before Open Enrollment

The window: Medicare Open Enrollment runs October 15 – December 7, 2026, and changes take effect January 1, 2027. This is the one annual window most people have to switch Medicare Advantage or Part D prescription drug plans for 2027.

What actually changed in the ratings formula: CMS’s Contract Year 2027 final rule removed 11 Star Ratings measures — mostly administrative metrics such as call-center performance (including interpreter and TTY availability) and appeals handling — and reinstated the general reward factor in place of the Health Equity Index (HEI). Because fewer operational metrics can pull a composite score down, a plan can show a higher star rating this year without its care having improved at all. CMS’s own regulatory analysis projects roughly $18.5B ($18.56 billion) flowing to plan sponsors over 10 years from these formula and bonus-payment changes. Only one genuinely new clinical measure was added for the 2027 measurement year: depression screening and follow-up.

What families should do — read under the headline star: Check the underlying categories (drug coverage, care coordination, and member experience with the care itself), then verify the three things that actually determine whether a plan works for your parent in 2027:

1. Their medications are on the plan’s 2027 formulary at a tolerable tier — confirm every routine prescription, tier placement, and any prior-authorization or step-therapy rules (alongside the finalized 2027 Part D $700 maximum deductible and $2,400 annual out-of-pocket cap).
2. Their doctors and hospital are in network for 2027 — provider networks change yearly, so check each primary care physician, specialist, and hospital by name in the plan’s 2027 directory.
3. Their pharmacy is preferred in-network — copays at a standard in-network pharmacy can be substantially higher than at a preferred in-network pharmacy under the same plan.

Check stars last, not first. A high-starred plan that drops your parent’s specialist or moves a daily medication to a non-preferred tier will cost your family far more than a lower-starred plan that covers their actual doctors and prescriptions.

Watch for the marketing surge: Federal broker and agent marketing restrictions were loosened effective October 1, 2026, so families should expect a higher volume of calls, mailers, and ads this season — and should know that a sales call is not advice. For free, unbiased guidance with no sales commission, contact your local State Health Insurance Assistance Program (SHIP) counselor, and review our live Medicare Open Enrollment 2026 key dates explainer, 2027 plan-ending checklist, 2027 Medicare costs guide, and FAQ entry (“When is Medicare Open Enrollment for 2026?”) for the dates and plan-ending rules.

Sources & 2027 rule-change explainers: CMS Contract Year 2027 Medicare Advantage and Part D Final Rule Fact Sheet; Medicare Star Ratings 2027 Rule-Change Explainer (Avidon Health, updated 2026-10-03); and 2027 Star Ratings Measure-Set & Reward-Factor Analysis (RISE Health, updated 2026-10-03).

Open Enrollment Is Live: Part D Costs Rise to a $700 Deductible and $2,400 Cap in 2027 — But 15 Drugs Get Negotiated Prices

The window and the deadline: Medicare Open Enrollment is open nationwide from October 15 through December 7, 2026, with coverage effective January 1, 2027. For more than 70 million enrolled beneficiaries (including approximately 47.4% projected by CMS in Medicare Advantage for 2027), doing nothing means your current coverage rolls over into its new 2027 price structure automatically — and 2027 is the year "set-and-forget" gets expensive.

Why headline averages mislead: The temporary federal Part D Premium Stabilization Demonstration (2025–2026) ends after 2026. While CMS projections show modest movement on average — projecting the average Medicare Advantage premium falling from $14.37 to $12 per month and average standalone Part D premiums increasing by less than $1 per month — individual plan premiums are swinging sharply. Regional reports show wide divergence: one popular Boston AARP/UnitedHealthcare PPO premium jumps +56%, while California’s median standalone Part D premium is reported up +41%. As plans re-price under the Inflation Reduction Act’s benefit restructuring, relying on national averages can conceal severe plan-level cost spikes.

The offsetting good news: On January 1, 2027, the first cycle of Medicare-negotiated drug prices takes effect for 15 widely used prescription drugs, including diabetes and weight-management therapy Ozempic, yielding substantial out-of-pocket relief for enrollees taking those specific therapies. In addition, insulin products remain capped at $35 per month and are exempt from the Part D deductible.

The 5-step caregiver check before December 7:

1. Read the Annual Notice of Change (ANOC): Review Section 1 to confirm whether your parent’s current plan is continuing, its 2027 premium, and deductible adjustments. (If their plan is terminating, read our Medicare Advantage plan exits guide for guaranteed-issue Medigap rights).
2. Run exact prescriptions through the Medicare Plan Finder: Use Medicare.gov to evaluate total annual cost (premiums plus deductibles plus tier-specific copays), not the headline monthly premium alone.
3. Confirm doctors and pharmacy network status: Check that primary physicians and specialists remain in-network for 2027, and confirm whether your filling pharmacy is categorized as a "preferred in-network" pharmacy.
4. Consider the Medicare Prescription Payment Plan: Spreads required Part D out-of-pocket costs into capped monthly installments across the year (note: this is a monthly budgeting tool only — it does not reduce total costs).
5. Get free, unbiased guidance: Contact your local State Health Insurance Assistance Program (SHIP) for free, one-on-one counseling without sales commissions.

Sources: Centers for Medicare & Medicaid Services (CMS) 2027 Part D parameters; Lone Star 92.5: Medicare Open Enrollment Begins, 2027 Plan Changes Announced (2026-10-15); Consumers’ Checkbook: Medicare Options and Advice (updated 2026-10-16); Money Digest: Retirees Face Historic Medicare Part D Deductible Hike in 2027 (2026-10).

Cannabis Oil Cut Late-Stage Dementia Agitation in 87% of Patients — What Families Should Know Before Asking Their Doctor

The burden of late-stage agitation: Agitation — pacing, vocal outbursts, restlessness, and acute physical distress — affects roughly half of late-stage dementia patients and is one of the most distressing symptoms families deal with. More than a third of patients keep experiencing severe agitation despite standard prescriptions such as benzodiazepines, opioids, or antipsychotics, all of which carry significant risks of their own in older adults with dementia, including heavy sedation, falls, and FDA boxed warnings.

What the LiBBY trial actually was: LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol) was an NIH-funded Phase 2 randomized, double-blind, placebo-controlled trial of 120 participants, all hospice-eligible with advanced dementia and clinically significant agitation. Participants received a standardized oral combination of 2 mg THC / 100 mg CBD twice daily for 12 weeks (dissolved in digestible oil) or placebo; results were presented at AAIC 2026 (London).

What it found — and the honest safety picture: At week 12, 87.2% of treated patients were rated improved on clinician global impression vs. 23.6% on placebo; the benefit appeared fast (a 6.27-point greater reduction on the CMAI agitation scale at week 2, p=0.0004) and held through week 12 (p<0.0001). Stated plainly alongside that benefit, overall adverse-event rates were similar to placebo (46.7% vs. 42.4%), but serious adverse events were higher in the treatment arm (23.3% vs. 11.9%), and deaths were 13.1% vs. 5.1% with no specific cause pattern — numbers that must be read in the context of an end-of-life population, and that families deserve to see unspun.

What to ask the doctor:

• Is agitation like my parent’s the kind this trial studied? (LiBBY studied hospice-eligible, late-stage dementia patients with clinically significant agitation — not earlier-stage wandering or mild sundowning.)
• What have we already tried, and what did it cost them? Review non-drug comfort measures and current medications, including whether sedatives or antipsychotics are causing side effects without relieving distress.
• If we were interested, what would the legal and hospice-policy position be in our state and with our hospice? State laws, facility licensing rules, and hospice protocols vary widely.
• What interactions with current sedatives or opioids would we watch for? Oral THC and CBD can amplify sedation, dizziness, and drug levels when combined with benzodiazepines, opioids, or antipsychotics.
• What would we monitor, and when would we stop? Agree in advance on specific target symptoms, side-effect warning signs, and a clear stopping rule.

Essential caveats for families: This evidence comes from a single Phase 2 trial in a hospice-eligible end-of-life population only; the studied oral THC/CBD formulation is not a prescription option today; there is no long-term data beyond the 12-week trial; and the legal status of THC/CBD products varies by state. Commercial dispensary or over-the-counter CBD/THC products are not equivalent to a standardized clinical-trial formulation, and nothing in this section is a recommendation to obtain or use cannabis products.

Sources: Psychiatric Times: Oral Cannabinoid From MediPharm Shows Significant Reduction in Agitation in Alzheimer Disease and Dementia (2026-10-03); and The Educated Patient: A CBD/THC Combination Reduced Dementia Agitation in Nearly 9 in 10 Patients (2026-10-04).

The Scan That Decides: Why a PET Scan Now Gates Who Gets Alzheimer’s Drugs — and When They Can Stop

Why a scan, not just symptoms: Clinical presentations from EANM’26 (European Association of Nuclear Medicine, Vienna, October 17–21, 2026) emphasize that brain PET imaging has shifted from an optional diagnostic aid to an essential treatment gatekeeper. Memory complaints alone do not justify initiating monoclonal antibody therapies. Objective confirmation of amyloid pathology is an absolute prerequisite for FDA-approved anti-amyloid treatments like lecanemab (Leqembi) and donanemab (Kisunla). A negative amyloid PET scan effectively rules out Alzheimer’s disease as the primary cause of symptoms, protecting patients from inappropriate therapy and unnecessary infusion risks.

Amyloid PET as the entry gate: Amyloid PET scans visualize insoluble amyloid-beta plaque deposition. Current FDA indications restrict these therapies strictly to individuals with confirmed pathology who are in the mild cognitive impairment (MCI) or mild dementia stages of Alzheimer’s disease. In clinical practice, high-accuracy plasma blood tests (measuring p-tau217 and Aβ42/40 ratios) and cerebrospinal fluid (CSF) assays are increasingly utilized as first-line screening filters, with PET imaging serving as the confirmatory gold standard. At academic centers such as LMU Munich’s Alzheimer Memorial Center, clinicians now conduct over 500 amyloid and tau PET scans annually as routine standard of care.

Tau PET for staging and response prediction: While amyloid indicates disease presence, tau PET measures neurofibrillary tangle density, mapping directly to symptom severity and neurodegeneration. In clinical trials, lower baseline tau burden strongly predicted superior cognitive slowing on donanemab, helping neurologists identify patients most likely to benefit before committing to an intensive infusion regimen.

Monitoring clearance and stopping treatment: Unlike indefinite chronic medications, follow-up amyloid PET scans can establish when brain plaques have been cleared below the detection threshold. In the Phase 3 donanemab trial, 52% of participants completed their treatment course in under 12 months (against a planned course of up to 18 months) after demonstrating amyloid-negative conversion — substantially reducing infusion burdens and long-term costs.

Essential safety questions for families to ask:

1. APOE ε4 genotyping: Have we completed genetic testing? Carriers of the APOE ε4 allele (especially homozygotes) face a significantly elevated risk of Amyloid-Related Imaging Abnormalities (ARIA), including brain edema (ARIA-E) and microhemorrhages (ARIA-H).
2. Required MRI monitoring schedule: What is the exact protocol for routine safety MRIs (typically at weeks 4, 12, 24, and 52) to check for asymptomatic ARIA?
3. Stopping benchmarks: Will follow-up amyloid PET scans be scheduled at 6 or 12 months to evaluate plaque clearance and determine if infusions can be paused?
4. Insurance and registry compliance: Does Medicare coverage apply under the CMS registry requirement, and what are the out-of-pocket costs for infusions, PET radiotracers, and MRIs?
5. Timing of intervention: Earlier diagnosis unlocks substantially greater lifetime quality of life and reduced caregiving strain — explore our companion analysis on starting Alzheimer’s treatment early and closing the diagnosis gap.

Sources: European Association of Nuclear Medicine (EANM’26, Vienna, Oct 17–21, 2026; presentations from LMU Munich Alzheimer Memorial Center); Medical Xpress: Brain PET Scans — Who Gets Alzheimer’s Drugs and Who Doesn’t (2026-10-16); HospiMedica: Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy (2026-10-17).